The role of intravenous dihydropyridine calcium channel blockers in the perioperative management of patients undergoing coronary artery bypass surgery

Current Vascular Pharmacology

Volumn 6, Issue 3, 2008, Pages 186-194

  Khoynezhad, Ali ^a   Dobesh, Paul P ^b   Stacy, Zachary ^c   Jalali, Ziba ^d  

^a NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c ST LOUIS COLLEGE OF PHARMACY   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Afterload reduction; Calcium channel blockers; Complications; Coronary artery bypass graft; Hypertension

Indexed keywords

AMLODIPINE; BENZOTHIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLEVIDIPINE; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; ENDOTHELIN 1; ESMOLOL; FELODIPINE; GLYCERYL TRINITRATE; HYDRALAZINE; ION CHANNEL; ISRADIPINE; LABETALOL; METOPROLOL; NICARDIPINE; NIFEDIPINE; NILVADIPINE; NIMODIPINE; NISOLDIPINE; NITRENDIPINE; NITROPRUSSIDE SODIUM; PHENYLALKYLAMINE; PLACEBO; VERAPAMIL; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

AGING; ANGINA PECTORIS; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; BRADYCARDIA; CELL INTERACTION; CHRONOTROPISM; CLINICAL TRIAL; CONTINUOUS INFUSION; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY RECANALIZATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG SOLUBILITY; DRUG TARGETING; EARLY INTERVENTION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART CONTRACTION; HEART FAILURE; HEART INFARCTION; HEART OUTPUT; HEMODYNAMICS; HUMAN; HYPERTENSION; INOTROPISM; MYOCARDIAL DISEASE; PERIOPERATIVE PERIOD; PHARMACODYNAMICS; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HYPERTENSION; PREVALENCE; PROTEIN TRANSPORT; REVIEW; RISK REDUCTION; SURGICAL PATIENT; SURGICAL TECHNIQUE; SURVIVAL; UNSPECIFIED SIDE EFFECT; VASOCONSTRICTION; VASODILATATION; WOUND HEALING; ANIMAL; PATHOPHYSIOLOGY;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CORONARY ARTERY BYPASS; DIHYDROPYRIDINES; HUMANS; PERIOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 53449095887     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016108784911993     Document Type: Review

References (100)

1. Rosamond W, Flegal K, Friday G, Furie K, Go A, Greenlund K, et al. Heart disease and stroke statistics - 2007 update. Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007; 115: e69-e171.
2. Estafanous FG, Tarazi RC. Systemic arterial hypertension associated with cardiac surgery. Am J Cardiol 1980; 46: 685-694.
3. Estafanous FG, Tarazi RC, Viljoen JF, El Tawil MY. Systemic hypertension following myocardial revascularization. Am Heart J 1973; 85: 732-8.
4. Gray RJ. Postcardiac surgical hypertension. J Cardiothorac Anesth 1988; 2: 678-682.
5. Kaplan JA, Jones EL. Vasodilator therapy during coronary surgery: comparison of nitroglycerin and nitroprusside. J Thorac Cardiovasc Surg 1979; 77: 301-309.
6. Seltzer JL, Gerson JI, Grogono AW. Hypertension in the perioperative period. NY State J Med 1980; 80: 29-31.
7. Gray RJ Bateman TM, Czer LSC, Conklin C, Matloff JM. Use of esmolol in hypertension after cardiac surgery. Am J Cardiol 1985; 56: 49F-56F.
8. Leung JM, O'Kelly BF, Mangano DT. Relationship of regional wall motion abnormalities to hemodynamic indices of myocardial oxygen supply and demand in patients undergoing CABG surgery. Anesthesiology 1990; 73: 802-814.
9. Brody WR, Kosek JC, Angell WW. Changes in vein grafts following aortocoronary bypass induced by pressure and ischemia. J Thorac Cardiovasc Surg 1972; 64: 847-854.
10. Eagle KA, Guyton RA, Davidoff R, Edwards FH, Ewy GA, Gardner TJ, et al. ACC/AHA 2004 Guideline Update for coronary artery bypass surgery - summary article. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to update the 1999 guidelines for coronary artery bypass graft surgery. J Am Coll Cardiol 2004; 44: 1146-54.
11. Serruys PW, Ong AT, van Herwerdern LA, Sousa JE, Jatene A, Bonnier JJ, et al. Five-year outcomes after coronary stenting vs. bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol 2005; 46: 575-581.
12. Brener SJ, Lytle BW, Casserly IP, Schneider JP, Topol EJ, Lauer MS. Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features. Circulation 2004; 109: 2290-2295.
13. Hoffman SN, TenBrook JA, Wolf MP, Pauker, SG, Salem DN, Wong JB. A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: one- to eight-year outcomes. J Am Coll Cardiol 2003; 41: 1293-1304.
14. Flaherty JT, Magee PA, Gardner TL, Potter A, Macallister NP. Comparison of intravenous nitroglycerin and sodium nitroprusside for treatment of acute hypertension developing after coronary artery bypass surgery. Circulation 1982; 65: 1072-1077.
15. Cohn NJ, Franciosa JA. Vasodilator therapy of cardiac failure. N Engl J Med 1977; 297: 27-31.
16. Knight PR, Lane GA, Hensinger RN, Bolles RS, Bjoraker DG. Catecholamine and renin-angiotensin response during hyoptensive anesthesia induced by sodium nitroprusside or trimethaphan camsylate. Anesthesiology 1983; 59: 248-253.
17. Benumof JL. Hypoxic pulmonary vasoconstriction and infusion of sodium nitroprusside. Anesthesiology 1979; 50: 481-483.
18. Becker L. Conditions for vasodilator-induced coronary steal in experimental myocardial ischemia. Circulation 1978; 57; 1103-1110.
19. Mann T, Cohn PF, Holman BL, Green LH, Markis JE, Phillips DA. Effect of nitroprusside on regional myocardial blood flow in coronary artery disease: results in 25 patients and comparison with nitroglycerin. Circulation 1978; 57: 732-738.
20. Kaplan JA, Dunbar RW, Jones EL. Nitroglycerin infusion during coronary-artery surgery. Anesthesiology 1976; 45: 14-21.
21. Brown GB, Bolson E, Peterson RB, Pierce CD, Dodge HT. The mechanisms of nitroglycerin action: stenosis vasodilation as a major component of the drug response. Circulation 1981; 64: 1089-1097.
22. Kaplan JA. Clinical considerations for the use of intravenous nicardipine in the treatment of postoperative hypertension. Am Heart J 1990; 119: 443-446.
23. CIBIS II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS II). Lancet 1999; 353: 9-13.
24. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
25. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e257-e354.
26. Hjalmarson A, Goldstein A, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT HF). JAMA 2000; 283: 1295-1302.
27. Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on survival in severe chronic heart failure. N Eng J Med 2001; 344: 1651-1658.
28. Wiest DE. A review of its therapeutic efficacy and pharmacokinetic characteristics. Clin Pharmacokinet 1995; 3: 190-202.
29. Dimich I, Lingham R, Gabrielson G, Singh PP, Kaplan JF. Comparative hemodynamic effects of labetalol and hydralazine in the treatment of postoperative hypertension. J Clin Anesth 1989; 1: 201-206.
30. Frishman W, Sica DA. Calcium channel blockers. In: Frishman W, Sonnenblick S, Sica DA eds. Cardiovascular Pharmacotherapeutics 2nd Ed. New York, New York McGraw-Hill 2003:105-130.
31. Morrow DA, Gersh BJ, Braunwald E. Chronic coronary artery disease. In: Zipes DP, Libby P, Bonow RO, Braunwald E, eds. Braunwald's Heart Disease. A textbook of Cardiovascular Medicine. 7th Ed, Philadelphia, Pennsylvania, Elsevier, Inc., 2005:1281-1354.
32. Opie LH. Calcium channel antagonists part III: use and comparative efficacy in hypertension and supraventricular arrhythmias. Cardiovasc Drugs Ther 1988; 1: 625-56.
33. Larach DR, Zelis R. Advances in calcium channel blocker therapy. Am J Surg 1986; 151: 527-37.
34. Braunwald E. Normal and abnormal myocardial function. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison's Principles of Internal Medicine. 15th Ed. New York, New York McGraw-Hill 2001:1309-18.
35. Catterall WA. Structure and regulation of voltage-gated calcium channels. Annu Rev Cell Dev Biol 2000; 16: 521-55.
36. Fox AP, Nowycky MC, Tsien RW. Kinetic and pharmacological properties distinguishing three types of calcium currents in chick sensory neurones. J Physiol 1987; 394: 149-72.
37. Takahashi M, Seagar MJ, Jones JF, Reber BF, Catterall WA. Subunit structure of dihydropyridine-sensitive calcium channels from skeletal muscle. Proc Natl Acad Sci USA 1987; 84: 5478-82.
38. Huber I, Wappl, E, Herzog A, Mitterdorfer J, Glossmann H, Langer T, et al. Conserved calcium-antagonist-binding properties and putative folding structure of a recombinant high-affinity dihydropyridine-binding domain. Biochem J 2000; 347: 829-36.
39. Wappl E, Mitterdorfer J, Glossmann H, Striessnig J. Mechanism of dihydropyridine interaction with critical binding residues of L-type calcium channel alpha 1 subunits. J Biol Chem 2001; 276: 12730-5.
40. Yamakage M, Namiki A. Calcium channels - basic aspects of their structure, function, and gene coding; anesthetic action on the channels: a review. Can J Anesth 2002; 49: 151-64.
41. Freedman DD, Waters DD. 'Second generation' dihydropyridine calcium antagonists: greater vascular selectivity and some unique applications. Drugs 1987; 34: 578-98.
42. Eichelbaum M, Echizen H. Clinical pharmacology of calcium antagonists: a critical review. J Cardiovasc Pharmacol 1984; 6(suppl 7): S963-7.
43. Follath F, Taeschner W. Clinical pharmacology of calcium antagonists. J Cardiovasc Pharmacol 1988; 12(suppl6): S98-100.
44. Kirsten R, Nelson K, Kirsten D, Heintz B. Clinical pharmacokinetics of vasodilators. Part 1. Clin Pharmacokinet 1998; 34: 457-82.
45. Braunwald E. Mechanism of action of calcium-channel blocking agents. N Engl J Med 1982; 307: 1618-27.
46. Nordlander M, Sjöquist PO, Ericsson H, Ryden L. Pharmacodynamic, pharmacokinetic, and clinical effects of clevidpine, an ultrashort-acting caclium antagonist for rapid blood pressure control. Cardiovasc Drug Rev 2004; 22: 227-50.
47. Goa KL, Sorkin EM. Nitrendipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs 1987; 33: 123-55.
48. Hogg KJ, Hornung RS, Hillis WS, Gupta S, Grant P, Singh SP. Anti-anginal efficacy of intravenous amlodipine assessed by means of atrial pacing. Postgrad Med J 1991; 67(suppl 5): S57-S58.
49. Vuylsteke A, Milner Q, Ericsson H, Mur D, Dunning J, Jolin-Mellgard A, et al. Pharmacokinetics and pulmonary extraction of clevidipine, a new vasodilating ultrashort-acting dihydropyridine, during cardiopulmonary bypass. Br J Anaest 2000; 85: 683-9.
50. Roche Palo Alto, Inc. Cardene prescribing information. Deerfield, Illinois; 2006.
51. Ramsch KD, Graefe KH, Scherling D, Sommer J, Ziegler R. Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine. Am J Nephrol 1986; 6(suppl 1): 73-80.
52. Engberding R, Bender F, Gulker H, Specker E, Molinski M. Hemodynamic effects of the new calcium antagonist nimodipine in normal and increased blood pressure. Z Kardiol 1984; 73: 498-503.
53. van der Wall EE, Cats VM, Chin JC, Pauwels EJ, Bruschke AV. Acute effects of intravenous nisoldipine on left ventricular function after acute myocardial infarction. Cardiovasc Drugs Ther 1994; 8(suppl 2): 345-51.
54. Wijeysundera DN, Beattie S, Rao V, Karski J. Calcium antagonists reduce cardiovascular complications after cardiac surgery. a meta-analysis. J Am Coll Cardiol 2003; 41: 1496-505.
55. Nathan HJ, Laganiere S, Dubé L, Foster B, McGilveray I, Harrison M, et al. Intravenous nifedipine to treat hypertension after coronary artery revascularization surgery. A comparison with sodium nitroprusside. Anesth Analg 1992; 74: 809-17.
56. Seitilberger R, Zwolfer W, Huber S, Schwarzacher S, Binder TM, Peschl F, et al. Nifedipine reduces the incidence of myocardial infarction and transient ischemia in patients undergoing coronary bypass grafting. Circulation 1991; 83: 460-468.
57. Bertolissi M, Antonucci F, De Monte A, Padovani R, Giordano F. Effects on renal function of a continuous infusion of nifedipine during cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1996; 10: 238-242.
58. Jeppsson A, Andersson L-G, Ekroth R, Joachimsson P-O. Renal hypoxanthine balance in cardiac surgery: effects of felodipine. J Cardiothorac Vasc Anesth 1999; 13: 715-719.
59. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary artery disease. Circulation 1995; 92: 1326-31.
60. Underwood SM, Feneck RO, Davies SW, Waleby RK, Lunnon MW. Use of isradipine in hypertension following coronary artery bypass surgery. Am J Med 1989; 86(suppl 4A): 81-87.
61. Leslie J, Brister N, Levy JH, Yared JP, Marty A, Martin H, et al. Treatment of postoperative hypertension after coronary artery bypass surgery. Double-blind comparison in intravenous isradipine and sodium nitroprusside. Circulation 1994; 90(5 Pt 2): II256-61.
62. Visser CA, Koolen JJ, van Wezel HB, Dunning AJ. Intracoronary application of nicardipine and nifedipine in coronary artery disease. Br J Clin Pharm 1986; 22: 313S-318S.
63. Visser CA, Koolen JJ, van Wezel HB, Dunning AJ. Hemodynamics of nicardipine in coronary artery disease. Am J Cardiol 1987; 59: 9J-12J.
64. Halpern NA, Alicea M, Krakoff LR, Greenstein R. Postoperative hypertension: a prospective, placebo-controlled, randomized, double-blind trial, with intravenous nicardipine hydrochloride. Angiology 1990; 41: 992-1004.
65. Goldberg ME, Clark S, Joseph J, Moritz H, Maguire D, Seltzer JL, et al. Nicardipine vs. placebo for the treatment of postoperative hypertension. Am Heart J 1990; 119: 446-50.
66. Halpern NA, Sladen RN, Goldberg JS, Neely C, Wood M, Alicea M, et al. Nicardipine infusion for postoperative hypertension after surgery for the head and neck. Crit Care Med 1990; 18: 950-955.
67. IV Nicardipine Study Group. Efficacy and safety of intravenous nicardipine in the control of postoperative hypertension. Chest 1991; 99: 393-98.
68. Halpern NA, Goldberg M, Neely C, Sladen RN, Goldberg JS, Floyd J, et al. Postoperative hypertension: a multicenter, prospective, randomized comparison between intravenous nicardipine and sodium nitroprusside. Crit Care Med 1992; 20: 1637-43.
69. Vecht RJ, Swanson KT, Nicolaides EP, Lennox SC, Gibson DG. Comparison of intravenous nicardipine and nitroglycerin to control systemic hypertension after coronary artery bypass grafting. Am J Cardiol 1989; 64: 19H-21H.
70. David D, Dubois C, Loria Y. Comparison of nicardipine and sodium nitroprusside in the treatment of paroxysmal hypertension following aortocoronary bypass surgery. J Cardiothorac Vasc Anesth 1991; 5: 357-361.
71. van Wezel HB, Koolen JJ, Visser CA, Dijkhuis JP, Vergroesen I, Moulijn AC, et al. Antihypertensive and anti-ischemic effects of nicardipine and nitroprusside in patients undergoing coronary artery bypass grafting. Am J Cardiol 1989; 64: 22H-27H.
72. van Wezel HB, Koolen JJ, Visser CA, Vergroesen I, Leyssius ATR, Dijkhuis JP, et al. The efficacy of nicardipine and nitroprusside in preventing poststernotomy hypertension. J Cardiothorac Anesth 1989; 6: 700-706.
73. Ericsson H, Bredberg U, Eriksson U, Jolin-Mellgård A, Nordlander M, Regårdh CG. Pharmacokinetics and arteriovenous differences in clevidipine concentrations following a short- and a long-term intravenous infusion in health volunteers. Anesthesiology 2000; 92: 993-1001.
74. Ericsson H, Tholander B, Regårdh CG. In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolised by esterases, in different animal species and man. Eur J Pharm Sci 1999; 8: 29-37.
75. Segawa D, Sjöquist PO, Nordlander M, Wang QD, Gonon A, Rydén. Cardiac inotropic vs. chronotropic selectivity of isardipine, nifedipine, and clevidipine, a new ultrashort-acting dihyropyridine. Eur J Pharmacol 1999; 380: 123-8.
76. Vuylsteke A, Milner Q, Ericsson H, Mur D, Dunning J, Jolin-Mellgård A, et al. Pharmacokinetics and pulmonary extraction of clevidipine, a new ultrashort-acting dihydropyridine, during cardiopulmonary bypass. Br J Anaesth 2000; 85: 683-9.
77. Astra Data on file. Blood pressure control in cardiac surgical patients. A double-blind comparison between clevidpine and placebo with addition of glyceryl trinitrate. Astra Hässle Report SH-SAD-0017. October 26, 2001.
78. Bailey JM, Lu W, Levy LH, Ramsay JG, Shore-Lesserson L, Prielipp RC, et al. Clevidipine in adult cardiac surgical patients. A dose-finding study. Anesthesiology 2002; 96; 1086-94.
79. Kieler-Jensen N, Jolin-Mellgård A, Nordlander M, Ricksten S-E. Coronary and systemic hemodynamic effects of clevidipine, an ultrashort-acting calcium antagonist, for treatment of hypertension after coronary artery surgery. Acta Anaesth Scand 2000; 44: 186-193.
80. Powroznyk AV, Vuylsteke A, Naughton C, Misso SL, Holloway J, Jolin-Mellgård A, et al. Comparison of clevidipine with sodium nitroprusside in the control of blood pressure after coronary artery surgery. Eur J Anaesthesiol 2003; 20: 697-703.
81. Chen AH, Nakao T, Brodman RF, Greenberg M, Charney R, Menegus M, et al. Early postoperative angiographic assessment of radial grafts used for coronary after bypass grafting. J Thorac Cardiovasc Surg 1996; 111: 1208-12.
82. Manasse E, Sperti G, Suma H, Canosa C, Kol A, Martinelli L, et al. Use of the radial artery for myocardial revascularization. Ann Thorac Surg 1996; 62: 1076-83.
83. Acar C, Ramsheyi A, Pagny JY, Jebara V, Barrier P, Fabiani JN, et al. The radial artery for coronary artery bypass grafting: clinical and angiographic results at five years. J Thorac Cardiovasc Surg 1998; 116: 981-989.
84. Possati G, Gaudino M, Prati F, Alessandrini F, Trani C, Glieca F, et al. Long-term results of the radial artery used for myocardial revascularization. Circulation 2003; 108: 1350-4.
85. Apostolidou IA, Skubas NJ, Despotis GJ, Kallinteri E, Hogue CW, Lappas DG, et al. Occurrence of myocardial ischemia immediately after coronary revascularization using radial arterial conduits. J Cardiothorac Vasc Anesth 2001; 15: 433-8.
86. He G-W, Yang C-Q. Comparative study on calcium channel antagonists in the human radial artery: clinical implications. J Thorac Cardiovasc Surg 2000; 119: 94-100.
87. Huraux C, Makita T, Szlam F, Nordlander M, Levy JH. The vasodilatory effects of clevidipine on human internal mammary artery. Anesth Analg 1997; 85: 1000-4.
88. Cable DG, Caccitolo JA, Pearson PJ, O'Brien T, Mullany CJ, Daly R, et al. New approaches to prevention and treatment of radial artery graft vasospasm. Circulation 1998; 98(suppl II): 15II-21II.
89. Possati G, Gaudino M, Alessandrini F, Luciani N, Glieca F, Trani C, et al. Midterm clinical and angiographic results of radial artery grafts used for myocardial revascularization. J Thorac Cardiovasc Surg 1998; 116: 1015-21.
90. Radermecker MA, Grenade T, Cao-Thian SK, Defraigne JO, Lavigne JP, Van Damme H, et al. Nicardipine protocol for CABG using the radial artery clinical and angiographic data. Acta Chir Belg 2001; 101: 185-9.
91. Taggart DP. The radial artery as a conduit for coronary artery bypass grafting. Heart 1999; 82: 409-10.
92. Samra SS Walwaikar PP, Morye VK, Gawda AG. Accelerated atherosclerosis. J Indian Med Assoc 2002; 100: 516-21.
93. Hamilton CA, Williams R, Pathi V, Berg G, McArther K, McPhaden AR, et al. Pharmacological characterization of endothelium-dependent relaxation in human radial artery: comparison with internal thoracic artery. Cardiovasc Res 1999; 42: 214-223.
94. Hamilton CA, Berg G, McArthur K, Reid JL, Dominczak AF. Does potassium channel opening contribute to endothelium-dependent relaxation in human internal thoracic artery? Clin Sci 1999; 96: 631-638.
95. Hanet C, Rousseau MF, Vincent M-F, Lavenne-Pardonge E, Pouleur H. Myocardial protection by intracoronary nicardipine administration during percutaneous transluminal coronary angioplasty. Am J Cardiol 1987; 59: 1035-1040.
96. Levin ER. Endothelins. N Engl J Med 1995; 333: 356-363.
97. Kiowski W. Endothelial function in humans. Studies of forearm resistance. Hypertension 1991; 18(suppl 4): 1184-9.
98. Iwase M, Yasufumi D, Goto D, Ichikawa K, Iino K, Yoshinari M, et al. Effect of nicardipine vs. enalapril on plasma endothelin-1 in hypertensive patients with type 2 diabetes mellitus. Clin Exper Hypertens 2000; 22: 695-703.
99. Nicholson AC, Etingin OR, Pomerantz KB, Summers BD, Friday K, Wolff AA, et al. Dihydropyridine calcium antagonists modulate cholesterol metabolism and eicosanoid biosynthesis in vascular cells. J Cell Biol 2004; 48: 393-400.
100. Puig-Parellada R, Planas JM, Gimenez J, Sanchez J, Gaya J, Tolosa E, et al. Plasma and saliva levels of PGI2 and TXA2 in the headache-free period of classical migraine patients. The effects of nicardipine. Headache 1991; 31: 156-158.